Financial News Feed

Stronger Sell Today VRNA ranks #5127 as SELL CANDIDATE. Weaker Sell
Today VRNA ranks #5127 as SELL CANDIDATE.

VRNA stock Verona Pharma plc

VRNA stock
Verona Pharma plc

Verona Pharma PLC American Depositary Share (VRNA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.... Read more
Wedbush reiterated their buy rating on shares of VERONA PHARMA P/S (NASDAQ:VRNA) in a research report sent to investors on Monday morning. “FDA approved Cabometyx (cabozantinib) for patients with ad... Read more
(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today. 1. Verona Pharma plc (VRNA) Lost 30.30% to close Monday's (Jan.14) trading at $6.97. N... Read more
VERONA PHARMA P/S (NASDAQ:VRNA)‘s stock had its “buy” rating reissued by research analysts at Wedbush in a research note issued on Monday. The analysts wrote, “FDA approved Cabometyx (cabozant... Read more
Investors may be searching high and low for the next breakout winner in the stock market. As companies continue to release quarterly earnings reports, investors will be looking for stocks that have th... Read more
Verona Pharma plc (VRNA) stock plunged to an all-time low of $5.76 on Monday as its lead chronic inflammatory lung disease treating drug failed to…... Read more
Shares of VERONA PHARMA P/S (NASDAQ:VRNA) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $5.65 and last traded at $6.30, with a volume of 380 shares traded. The ... Read more
VERONA PHARMA P/S (NASDAQ:VRNA) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $5.65 and last traded at $6.30, with a volume of 380 shares. The stock had previ... Read more
VERONA PHARMA P/S (NASDAQ:VRNA) has received a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated ... Read more
Even though short-term trading can be very profitable, it can also be a huge risk. Short-term lasts from anywhere from a few minutes or several days or weeks. Traders have to truly understand the risk... Read more
VERONA PHARMA P/S (NASDAQ:VRNA) has been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities researc... Read more
VERONA PHARMA P/S (NASDAQ:VRNA) has received an average recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. One research analyst ... Read more
According to the latest stock data, investors are looking at Verona Pharma plc (:VRNA)’s short data and trying to figure out market sentiment on which way the market thinks the stock is moving. The ... Read more
Though short-term trading can be very lucrative, it can also be very risky. Short-term trading can last for only a few minutes or several days or weeks. Traders must understand the risks and the rewar... Read more
The stock of Verona Pharma Plc - American Depositary Share (NASDAQ:VRNA) registered a decrease of 16.67% in short interest. VRNA's total short interest was... Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank